Related Experiment Videos
[Intra-arterial chemoembolization with albumin microspheres including mitomycin C in inoperable hepatic cancer]
Abstract:
Intra-arterial chemoembolization using mitomycin C microsphere (MMC MS) was carried out both for VX-2 tumor-bearing rabbits and for 19 patients with inoperable hepatic cancer. MMC MSs contain 5% MMC in albumin as a biodegradable drug carrier and an average diameter is 45 +/- 8 microns. VX-2 tumor, implanted into the hind legs of the rabbits, was treated intraarterially when it grew up to 2 cm in diameter. Tumor growth was compared with the other treated groups such as control, conventional MMC or blank microsphere; and MMC concentrations in the peripheral blood, femoral vein blood and muscles of the hind legs were measured after treatment. Tumor growth in the MMC MS group was remarkably retarded, but the other groups had no retardation. MMC concentrations of blood and muscle dropped below the assay limitation within 2 hours after conventional MMC injection, but in the animals treated with MMC MS, those showed the sustained drug release over for 6 hours. Fifteen patients with unresectable hepatic malignancies received intra-arterial hepatic infusion using conventional MMC, while 19 patients were treated by MMC MS infusion. Tumor regression in the 19 patients with MMC MS was seen in 42% (8/19), while that in the 15 with conventional infusion in 33% (5/15). Serum CEA levels in 12 patients with metastatic cancer decline from 57.7 +/- 72.2 ng/ml to 16.5 +/- 21.6 ng/ml 2 weeks after MMC MS treatment. However, those in 10 patients given conventional infusion dropped from 24.0 +/- 18.1 ng/ml to 17.4 +/- 18.0 ng/ml. The survival duration for patients given conventional infusion was 6.7 +/- 2.8 months, but that with MMC MS prolonged to 14.1 +/- 8.9 months. The MMC MS treatment for metastatic hepatic cancer had superiority to the conventional infusion treatment at p = 0.0040 in survival rate.
Insights
Mitomycin C microsphere (MMC MS) intra-arterial chemoembolization significantly retarded VX-2 tumor growth in rabbits. In patients with hepatic cancer, MMC MS improved tumor regression and survival rates compared to conventional mitomycin C infusion.
Area of Science:
- Oncology
- Biomedical Engineering
- Pharmacology
Context:
- Unresectable hepatic cancer presents significant treatment challenges.
- Conventional intra-arterial chemotherapy offers limited efficacy and sustained drug delivery.
- Microsphere-based drug delivery systems show promise for targeted cancer therapy.
Purpose:
- To evaluate the efficacy of intra-arterial chemoembolization using mitomycin C microspheres (MMC MS) for hepatic cancer.
- To compare the therapeutic outcomes of MMC MS with conventional mitomycin C infusion in preclinical and clinical settings.
- To assess the pharmacokinetic profile and tumor growth inhibition of MMC MS.
Summary:
- Intra-arterial chemoembolization with MMC MS demonstrated remarkable retardation of VX-2 tumor growth in rabbits compared to control and conventional MMC treatments.
- In patients with unresectable hepatic malignancies, MMC MS infusion resulted in higher tumor regression rates (42%) versus conventional MMC infusion (33%).
- Sustained drug release from MMC MS over 6 hours was observed, contrasting with rapid clearance of conventional MMC.
Impact:
- MMC MS treatment significantly improved survival duration in hepatic cancer patients, prolonging it to 14.1 months compared to 6.7 months with conventional infusion (p = 0.0040).
- Serum CEA levels decreased more substantially in patients treated with MMC MS, indicating greater therapeutic response.
- These findings highlight the superiority of MMC MS chemoembolization for treating metastatic hepatic cancer, offering improved survival and therapeutic efficacy.